Lyra Therapeutics, Inc., a clinical-stage therapeutics company, announced that the first patient was treated in the Part 1/non-randomized portion of the phase 2 BEACON clinical trial of LYR-220 in adult patients with chronic rhinosinusitis (CRS) who have had a prior sinus surgery. LYR-220 is specifically designed to deliver six months of continuous anti-inflammatory medication in a controlled and consistent fashion to the sinonasal passages for the millions of CRS patients that continue to require treatment despite a prior surgery. Topline results from Part 1 of the phase 2 BEACON trial are expected around year end.
"We have limited and often ineffective treatment options to alleviate persistent, burdensome symptoms in CRS patients that have been previously operated on," said Anders Cervin, MD, PhD, Professor Chair in Otolaryngology at the Centre for Clinical Research, Royal Brisbane & Women's Hospital Campus, Herston, in Queensland, Australia, and Principal Investigator in the BEACON study. "LYR-220 could represent a meaningful advance in care for these underserved patients, the majority of whom have no approved drug treatment options."
The phase 2 BEACON trial is a controlled parallel-group study to evaluate safety, tolerability, pharmacokinetics, and efficacy comparing two designs of the LYR-220 (7500
